Essential Resources
Provider Information
Patient Information
From Our Sponsors
Atopic Dermatology Quiz Challenge
Test your knowledge of atopic dermatitis with this quiz and enter for a chance to win a $500 amazon gift card. Show your smarts about pathophysiology, treatments like PDE4 inhibitors, and management strategies
The Toll of Atopic Dermatitis is More than Skin Deep: Q & A with Harvard Child Psychologist Jennifer LeBovidge, PhD
Awareness of the psychological burden of eczema is improving, LeBovidge says, but if clinicians don't address mental health, patients and families will suffer in silence.
In Patients with Skin of Color, Lebrikizumab for Atopic Dermatitis Gets High Marks for Treatment Satisfaction
In individuals with skin of color with AD, lebrikizumab was associated with improved QoL and importantly with high rates of patient-reported treatment satisfaction.
Atopic Dermatitis Update: Roflumilast 0.15% Cream Shows Long-Term Safety and Efficacy Plus Benefit with Proactive Use
Improvement in AD signs and symptoms continued through 56 weeks of treatment with the PDE4 inhibitor including when used just twice weekly as prophylaxis.
Dermatology Therapeutics: Updates for Primary Care from AAD 2025
Research included new findings on topical and systemic treatments for atopic dermatitis, psoriasis, alopecia areata, and other chronic skin disorders.
Early-Onset Atopic Dermatitis Significantly Impacts Psychosocial Development, Wellbeing Throughout Adult Life
The impact of childhood onset AD on adult psychosocial experience is far reaching and profound according to findings from the Scars of Life Survey.
Contact Dermatitis: Expert Insights on First-Line and Emerging Therapies
JiaDe 'Jeff' Yu, MD, discusses first-line therapies, emerging biologics, and the potential of molecular biomarkers for improved diagnosis.
sNDA for Roflumilast Cream 0.05% for the Treatment of AD in Children Aged 2 to 5 Years Gets FDA Nod
The FDA has set a PDUFA target action date for October 13, 2025, according to Arcutis Biotherapeutics.
Late Breakers in Atopic Dermatitis: Highlights and Previews with Alexandra Golant, MD
From the revolutionary approval of dupilumab to the promise of potential disease modification with OX40 inhibitors, Golant provided a wide-ranging update of the treatment space.
4 Pearls for Managing Atopic Dermatitis
From black tea compresses to effective mind-body interventions for symptom control, Peter Lio, MD, shares 4 pearls for effective AD management.
10 Dermatology Tips for Primary Care
The dermatologic tips offered in this short slide show come from 4 renowned professionals and reflect their subspecialties.
Atopic Dermatitis Treatments Up Close: Biologics, JAK Inhibitors, and Cytokines, Oh My
Atopic dermatitis management will be the topic of a debate over treatment with biologics and JAK inhibitors and in a focused session on the role of IL-13 in the chronic skin disease.
Dupilumab Drug Survival Rates Superior to Those for Upadacitinib and Tralokinumab in Atopic Dermatitis: Large-Scale, Real-World Data
A first large-scale comparison of length of treatment with advanced AD therapies also identified reasons for discontinuation and examined prior use of biologics and JAK inhibitors.
When is It Time to Refer? A Dermatologist Considers Atopic Dermatitis Treated in Primary Care
Up to 80% of atopic dermatitis is managed in primary care but some patients will need a higher level of care. Dr Mona Shahriari discusses factors that point to referral.
